KH 617
Alternative Names: KH-617Latest Information Update: 03 Feb 2023
At a glance
- Originator Chengdu Kanghong Pharmaceutical
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Dec 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in China (Injection) (NCT05667194)